SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Intel Corp. engages in the design, manufacture, and sale of computer products and technologies. It delivers computer, networking, data storage, and communications platforms. The firm operates through the following segments: Client Computing Group (CCG), Data Center and AI (DCAI), Intel Foundry Services (IFS), and All Other. The CCG segment consists of platforms designed for notebooks, 2-in-1 systems, desktops, tablets, phones, wireless and wired connectivity products, and mobile communication components. The DCAI segment delivers solutions to cloud service providers and enterprise customers, along with silicon devices for communications service providers and high-performance computing customers. The IFS segment refers to full stack solutions created from the foundry industry ecosystem. The All Other segment represents results from other non-reportable segments and corporate-related charges. The company was founded by Robert Norton Noyce and Gordon Earle Moore on July 18, 1968, and is headquartered in Santa Clara, CA.

Intel Corp.

Intel Corp

Intel is rallying as investors react to a strategic $14.2 billion deal to regain full ownership of its Ireland-based Fab 34, a move perceived as a major vote of confidence in the company's manufacturing and AI-driven growth trajectory. The community is actively debating the stock's future, with many interpreting the heavy capital reinvestment as a clear indicator that major new customer contracts are imminent.

Netflix, Inc. engages in providing entertainment services. It also offers activities for leisure time, entertainment video, video gaming, and other sources of entertainment. It operates through the United States and International geographic segments. The company was founded by Marc Randolph and Wilmot Reed Hastings on August 29, 1997 and is headquartered in Los Gatos, CA.

Netflix Inc.

Netflix Inc

Netflix is trending as the market reacts to the company's latest subscription price hikes, which analysts view as a strategic move to fund a massive content budget and solidify profitability. While some retail investors are voicing frustration over recurring cost increases, the community is heavily focused on the stock's relative strength and technical breakout potential, with many discussing its role as a hedge against broader market volatility.

Soleno Therapeutics, Inc. operates as clinical-stage biopharmaceutical company, which engages in the development and commercialization of novel therapeutics for the treatment of rare diseases. It focuses on the treatment of metabolic and neurobehavioral disorder. It offers its lead candidate, Diazoxide Choline Controlled-Release (DCCR), an oral tablet for the treatment of Prader-Willi Syndrome (PWS). The company was founded on August 25, 1999 and is headquartered in Redwood City, CA.

Soleno Therapeutics Inc

Soleno Therapeutics is currently trending following news that it has secured FDA approval for VYKAT XR, the first therapy developed to treat hyperphagia in Prader-Willi syndrome. The community is actively discussing the stock's significant price momentum, debating the potential for a future acquisition by a larger pharmaceutical player, and evaluating the long-term commercial execution of this newly approved asset.

Luckin Coffee, Inc. engages in providing food and beverage items, and operates coffee retail stores. It has a pioneered a technology-driven retail network to provide coffee and other products of high quality, high convenience and high affordability to customers. The company manages pick-up stores, relax stores, and delivery kitchens. It also offers tea, snacks, and light meals through its mobile application. The company was founded by Zhi Ya Qian, Fei Yang and Jin Yi Guo on June 16, 2017 and is headquartered in Xiamen, China.

Luckin Coffee Inc - ADR

Luckin Coffee is currently trending as shareholders analyze the strategic implications of parent company Centurium Capitals acquisition of Blue Bottle Coffee. While the community remains divided over potential conflicts of interest versus synergistic growth, investors are closely monitoring for signs of a long-anticipated U.S. exchange relisting and are actively debating the stock's future valuation amid shifting institutional ownership.

“Buttcoin - The Next Bitcoin” is the memecoin version of Bitcoin. Launched on January 30, 2025, on Pump.fun, it’s a community-owned memecoin on Solana. The idea was inspired by a 4:20 minutes long YouTube video from 2013 called "The Next Bitcoin?" by James D. McMurray.

The Next Bitcoin

Investors are rallying behind this Solana-based meme coin as a satirical movement intended to mock established market structures, with community members actively comparing its long-term potential to industry giants. Discussions are currently dominated by enthusiasts promoting the token's cultural narrative and its goal of creating viral engagement within the broader crypto ecosystem.

Neurocrine Biosciences, Inc. is a neuroscience-focused, biopharmaceutical company, which engages in the research and development, commercialization, and sale of pharmaceuticals for the treatment of neurological, neuroendocrine, and neuropsychiatric disorders. Its portfolio of products includes treatments for tardive dyskinesia, chorea associated with Huntington's disease, classic congenital adrenal hyperplasia (CAH), and endometriosis and uterine fibroids. The company was founded by Kevin C. Gorman and Wylie W. Vale in January 1992 and is headquartered in San Diego, CA.

Neurocrine Biosciences, Inc.

Neurocrine Biosciences is trending as the market reacts to the definitive agreement to acquire Soleno Therapeutics for $2.9 billion. Community sentiment is mixed, with active debate regarding whether the acquisition effectively addresses Neurocrine's need for pipeline growth or if the premium paid for the rare-disease asset signals a strategic overpay.

Praxis Precision Medicines, Inc. is a clinical-stage biopharmaceutical company, which engages in the genetic epilepsies into the development of therapies for central nervous system, or CNS, disorders characterized by neuronal excitation-inhibition imbalance. It focuses on two proprietary platforms: Cerebrum and Solidus. The Cerebrum platform utilizes a deep understanding of neuronal excitability and neuronal networks and applies a series of computational and experimental tools to develop orally available precision therapies. The Solidus platform consists of antisense oligonucleotide, or ASO. The company was founded by Kiran Reddy, David Goldstein, and Steven Petrou on September 22, 2015 and is headquartered in Boston, MA.

Praxis Precision Medicines Inc

Praxis Precision Medicines is experiencing a significant surge in momentum as the company reports positive trial results for its essential tremor and epilepsy therapies, driving multiple analyst price target upgrades. While the community is debating the impact of a recent large-scale public offering, many investors remain bullish on the long-term potential of the company's CNS-focused pipeline.

Altria Group, Inc. is a holding company, which engages in the manufacture and sale of cigarettes in the United States. It operates through the following segments: Smokeable Products, Oral Tobacco Products, and All Other. The Smokeable Products segment consists of cigarettes manufactured and sold by PM USA, and machine-made large cigars and pipe tobacco manufactured and sold by Middleton. The Oral Tobacco Products segment includes MST and snus products manufactured and sold by USSTC, and oral nicotine pouches manufactured and sold by Helix. The All Other segment refers to the financial results of NJOY, Helix ROW, and the IQOS System heated tobacco business. The company was founded in 1919 and is headquartered in Richmond, VA.

Altria Group Inc.

Altria Group is seeing significant investor interest driven by a combination of resilient pricing power in its core smokeable business and ongoing momentum in its smoke-free portfolio, particularly with the growth of its on! nicotine pouches. The community is actively debating the company's long-term pivot from traditional cigarettes toward smoke-free alternatives, with many highlighting the stock's role as a classic, high-yield defensive play in a volatile market.

iShares Trust - iShares U.S. Transportation ETF

iShares Dow Jones Transportation Average

The iShares Dow Jones Transportation Average is experiencing significant volatility as investors debate the impact of rising fuel costs, labor disputes, and shifting freight demand on the broader economy. Market participants are closely watching the sector for signs of a potential recession or economic cooling, often using the ETF as a key indicator of market breadth and institutional sentiment.

Nokia Oyj engages in the provision of network infrastructure, technology, and software services. It operates through the following segments: Mobile Networks, Network Infrastructure, Cloud and Network Services, and Nokia Technologies. The Mobile Networks segment offers technologies for Radio Access Networks (RAN) as well as Microwave Radio Links (MWR) for transport networks. The Network Infrastructure serves communication service providers, enterprises, webscales and public sector customers. The Cloud and Network Services segment builds around software and the cloud and is focused on driving leadership in cloud-native software and as-a-service delivery models, as demand for critical networks accelerates; and with strong market positions in communications software, private wireless networks, and cognitive (or intelligent) services. The Nokia Technologies segment, building on decades of innovation and R&D leadership in technologies used in virtually all mobile devices used today, is expanding the Nokia patent licensing business, reintroducing the Nokia brand to smartphones through brand licensing, and establishing a technology licensing business. The company was founded by Fredrik Idestam in 1865 and is headquartered in Espoo, Finland.

Nokia Corp - ADR

Nokia Corp

Nokia is trending as retail and institutional investors highlight increasing institutional accumulation and strategic partnerships in the AI infrastructure space, leading to significant options activity. Community members are actively debating the stock's long-term potential as a key player in 5G and 6G network deployment while monitoring its breakout above recent resistance levels.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

The Zacks Analyst Blog  SDY, NOBL, OUSA and PFM

Amid oil-driven volatility and inflation worries, dividend aristocrat ETFs like NOBL draw attention as investors seek steady income and resilient equity exposure.

Play Dividend Growth ETFs With a Long-Term View 

Oil turmoil, inflation worries and market volatility are reviving interest in dividend growth ETFs that offer steady income and quality exposure.

Should Invesco Dividend Achievers ETF (PFM) Be on Your Investing Radar?

Agilent Technologies, Inc. (<a class="mention" data-mention="$A" data-symbol-id="A" href="https://stocktwits.com/symbol/A" target="_blank">$A</a>), a provider of analytical and clinical laboratory technologies, is due to report its fiscal year 2024 fourth-quarter results after the market closes on Monday, and the company is widely expected to report modest declines in both the top- and bottom-line.Analysts, on average, expect Santa Clara, California-based Agilent to report non-GAAP earnings per share (EPS) of $1.32, lower than the year-ago’s $1.38. The consensus calls for a decline in revenue from $169 billion to $1.67 billion.&nbsp;In late-August, the company’s guided to non-GAAP EPS of $1.38-$1.42 and revenue of $1.64 billion to $1.69 billion.Agilent, which was splintered from Hewlett-Packard Co. ($HPQ) in 1999, provides full-range of solutions including instruments, software, services and expertise. It caters to six key markets, namely food, pharmaceuticals, chemical &amp; advanced materials, environmental &amp; forensics, diagnostics and research.Last week, the company announced a 5% increase in its quarterly cash dividend to $0.248. The dividend would be paid on Jan. 22, 2025 to shareholders of record as of the close of business on Dec. 31, 2024.During the quarter, Agilent completed the acquisition of Canadian contract development and manufacturing organization Biovectra. It also announced Mito-rOCR Assay kit, an end-to-end solution that makes&nbsp;sophisticated analysis of mitochondrial function available to researchers of all skill levels.Agilent’s updated full-year guidance issued in August model non-GAAP EPS of $5.21-$5.25 and revenue of $6.45 billion-$6.50 billion.&nbsp;<figure class="image"><a href="https://stocktwits.com/symbol/A"><img style="aspect-ratio:635/127;" src="https://st-everywhere-cms-prod.s3.us-east-1.amazonaws.com/a_sentiment_76485e9d20.png" alt="a-sentiment.png" width="635" height="127"></a><figcaption>A sentiment and message volume November 24, 2024, as of 10:47 pm ET | Source:&nbsp;Stocktwits</figcaption></figure>Users of the Stocktwits platform are largely 'bearish' (40/100) on Agilent stock, while message volume remained 'normal.'Agilent’s shares have declined 3.25% for the year-to-date period. The shares ended Friday’s session up 1.35% at $133.84.In mid-October, Barclays analyst Luke Sergott upped the price target for the stock from $135 to $145, while maintaining an 'Underweight' rating,&nbsp;<a target="_blank" rel="noopener noreferrer nofollow" href="https://thefly.com/news.php?symbol=A">according</a> to the Fly.For updates and corrections email newsroom[at]stocktwits[dot]com.Read Next:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/bath-and-body-works-analyst-cautious-ahead-of-q3-print-retail-sentiment-deflates/cJIfbuGRg7">Bath &amp; Body Works Analyst Cautious Ahead Of Q3 Print: Retail Sentiment Deflates</a>

Agilent recently announced a 5% hike to its quarterly dividend: 

Agilent To Report Q4 Results Monday: Retail Sentiment Downbeat

Agilent’s shares have declined 3.25% for the year-to-date period, underperforming the broader market.

Equity

Agilent’s shares have declined 3.25% for the year-to-date period, underperforming the broader market.


Invesco Exchange-Traded Fund Trust - Invesco Dividend Achievers ETF

Opendoor ($OPEN)

Strategy ($MSTR)

American Eagle ($AEO)

Ondas Inc. ($ONDS)

The stock that proved the power of the crowd. Fueled by community energy and social momentum, this winner captivated retail investors regardless of what the "experts" or traditional fundamentals had to say.

PFM
Invesco Dividend Achievers ETF

Feed

News

Sentiment

Fundamentals

Info

Poll

Latest PFM News

PFMInvesco Dividend Achievers ETF